Actively Recruiting
Studying the Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases: Analysis on Renal Biopsies
Led by Meyer Children's Hospital IRCCS · Updated on 2024-03-22
200
Participants Needed
1
Research Sites
36 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the role of renal progenitors and polyploid tubular cell responses in kidney diseases affecting children and adolescents up to 17 years old. The focus is on how certain kidney cells, including parietal epithelial cells (PECs) and tubular progenitors, contribute to kidney damage and regeneration in conditions such as chronic kidney disease (CKD) and acute kidney injury (AKI). This research aims to better understand disease progression by examining kidney biopsy samples using advanced super resolution imaging techniques, linking cellular findings to clinical data and markers of kidney damage. The study involves patients with kidney diseases who are undergoing diagnostic kidney biopsies. The research evaluates renal progenitors in the biopsies to explore their role in disease mechanisms and progression. Clinical data will be collected at the time of biopsy and then at 3, 6, and 12 months, followed by annual follow-ups for up to 9 years. These assessments include DNA and RNA analyses to study tubular cell behavior during AKI and its impact on kidney injury. Participants will have kidney biopsies as part of their clinical care, with additional analyses performed for research purposes. Clinical information will be gathered repeatedly over several years to monitor disease progression and cell activity. The main outcome measured is the role of renal progenitors in glomerular disease progression, with secondary outcomes focused on tubular cell responses during AKI. This long-term follow-up aims to provide insights linking cellular changes in biopsies with patient clinical outcomes.
CONDITIONS
Brief Title
The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with glomerular diseases undergoing renal biopsy (e.g., rapidly progressive glomerulonephritis, minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, lupus nephritis, membranous nephropathy, IgA nephropathy, etc)
- Patients with acute kidney injury (AKI), regardless of the nature of the damage (septal, ischemic, toxic, or unknown)
- Signed informed consent form
You will not qualify if you...
- Sample insufficient and/or unavailable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for renal biopsy
Duration - Up to 9 years
Participants are monitored to evaluate clinical data related to kidney disease progression and mechanisms of acute kidney injury.
Visits at 3, 6, and 12 months from enrollment, then annual visits
Trial Site Locations
Total: 1 location
1
Meyer Children's Hospital IRCCS
Florence, Italy
Actively Recruiting
Research Team
P
Paola Romagnani, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here